Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

162
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
162
Clinical Trials01:16

Clinical Trials

7.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.0K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

362
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
362
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.2K
Blinding01:11

Blinding

2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
Hazard Ratio01:12

Hazard Ratio

219
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
219

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changing standard of care during a randomized trial: examples, considerations and guidelines.

Journal of the National Cancer InstituteĀ·2026
Same author

Molecular Profiling for Precision Oncology: Moving Beyond Feasibility and Safety.

Journal of clinical oncology : official journal of the American Society of Clinical OncologyĀ·2026
Same author

A note on rank-preserving structural failure time models to account for crossover.

Clinical trials (London, England)Ā·2026
Same author

Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials.

Clinical trials (London, England)Ā·2025
Same author

Accrual Suspensions in Seamless Phase II/III Trials: A Review of NRG Oncology Trials.

JCO oncology advancesĀ·2025
Same author

Non-inferiority trials: tyranny or good governance?

The Lancet. OncologyĀ·2025

Related Experiment Video

Updated: Aug 27, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.6K

Augmenting randomized clinical trial data with historical control data: Precision medicine applications.

Boris Freidlin1, Edward L Korn1

  • 1Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.

Journal of the National Cancer Institute
|September 26, 2022
PubMed
Summary

Augmenting small clinical trials with historical data is challenging in precision medicine. Strategies for using historical controls are unlikely to be effective for small, targeted patient groups.

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.3K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

748

Related Experiment Videos

Last Updated: Aug 27, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.6K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.3K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

748

Area of Science:

  • Clinical Trials
  • Precision Medicine
  • Biostatistics

Background:

  • Precision medicine yields smaller patient subpopulations, complicating randomized clinical trials (RCTs).
  • Augmenting small RCTs with historical control data is a proposed solution for timely trials.
  • Existing strategies aim to mitigate bias when incorporating external control data.

Purpose of the Study:

  • To evaluate the utility of proposed strategies for using historical control data in precision medicine.
  • To demonstrate the limitations of these strategies with simple examples and case studies.

Main Methods:

  • Analysis of strategies for augmenting RCT control arms with historical data.
  • Illustrative examples and review of completed studies.

Main Results:

  • The evaluated strategies are unlikely to be effective for precision medicine applications.
  • Challenges remain in leveraging historical data for small, targeted patient populations.

Conclusions:

  • Current methods for incorporating historical controls are not well-suited for the unique challenges of precision medicine.
  • Further research is needed to develop robust methods for small-sample clinical trials in targeted therapies.